SEC Filing Summary: Nemus Bioscience, Inc. (Form 10-K)
Entity and period: The supplied metadata names Skye Bioscience, Inc., but this filing is for Nemus Bioscience, Inc. (Nevada), for the fiscal year ended December 31, 2018; it is an annual report, not a standalone fourth-quarter report. The filing says the board approved a proposed name change to Emerald Bioscience, Inc. in February 2019. The filing text does not identify Skye Bioscience as the registrant.
Business context
Nemus was an early-stage biopharmaceutical company developing cannabinoid-based therapeutics under licenses and research agreements with the University of Mississippi (UM). It had no product revenue and no approved products. Its pipeline comprised NB1111, a THC prodrug for glaucoma (preclinical); NB2222, a CBD analog for ocular indications (preclinical); and NB3111, a cannabinoid program targeting MRSA (research stage). The company relied substantially on UM and third-party manufacturers and research providers.
Financial results and liquidity
| Metric | FY 2018 / Dec. 31, 2018 | FY 2017 / Dec. 31, 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $330,000 | $311,000 |
| General and administrative expense | $4.363 million | $3.548 million |
| Total operating expenses / operating loss | $4.693 million | $3.859 million |
| Net loss | $19.194 million | $3.094 million |
| Basic and diluted loss per share | $0.16 | $0.11 |
| Cash used in operating activities | $3.943 million | $3.331 million |
| Cash and cash equivalents | $1.853 million | $260,000 |
Operating expenses rose about 22%; net loss increased sharply, primarily due to financing- and warrant-related non-operating charges. These included $6.503 million from changes in derivative fair value and $7.175 million from the initial fair value of Emerald financing warrants exceeding financing proceeds. The filing reports no revenue, so a revenue-based margin is not meaningful; no gross margin is reported.
At year-end, total assets were $1.957 million, total liabilities $17.519 million, working capital deficit $13.985 million, accumulated deficit $33.225 million, and stockholders’ deficit $15.562 million. Current derivative liabilities were $15.739 million. The company had $2.0 million principal outstanding under its related-party credit facility, carried at $1.361 million net of discounts and issuance costs; the filing estimated the advance’s fair value at $3.177 million. The $20 million facility bears 7% interest, matures October 2022, and is convertible at Emerald’s option at $0.40 per share. It had $18 million undrawn at year-end, subject to board approval. A further $2 million was drawn in February 2019.
Management said available cash would fund requirements for at least three months, while also stating that, without additional funding, the company could not meet obligations beyond one year after the financial statements were issued. The auditor’s report highlighted recurring losses and substantial doubt about the company’s ability to continue as a going concern. Operating cash burn was partly offset by $5.541 million of financing cash inflows in 2018. The filing reports no material off-balance-sheet arrangements.
Material changes, outlook and risks
- Emerald became the controlling investor in January 2018, leading to a board and management transition. In 2018, the company issued 32.5 million shares in Emerald-related financings, converted remaining preferred stock into common shares, and ended the year with 133.9 million common shares outstanding, versus 33.6 million at the prior year-end.
- Emerald’s 2018 equity financing raised $3.25 million gross and included 44.2 million warrants with a $0.10 exercise price and anti-dilution provisions. The separate credit facility also carries conversion and warrant features. These arrangements create potential dilution and substantial fair-value accounting volatility.
- Management planned to prioritize ocular development, especially NB1111, and described further preclinical work and a potential IND submission followed, if permitted, by human studies. These were plans, not firm guidance or assured milestones. The filing gives no revenue or earnings guidance.
- Previously reported rabbit studies showed IOP reductions for NB1111, including approximately 38% at the higher concentration using a nanoparticle delivery approach. These are preclinical findings, not evidence of clinical efficacy or safety in humans.
- Key risks include the need for additional financing; dependence on UM and external contractors; early-stage, unproven drug candidates; FDA and DEA approval, controlled-substance registration and scheduling requirements; manufacturing and clinical-trial risks; and competition, reimbursement uncertainty, and potential dilution. Cannabis and some cannabinoids remain Schedule I substances under federal law.
- The company was pursuing arbitration over a failed $20 million Series E financing and related guarantee. The guarantor had not paid, and the company said its counsel would not proceed and that it was assessing whether to continue pursuing remedies. Recovery is uncertain.
- Related-party arrangements warrant attention: Emerald provided financing and consulting services, incurred $550,000 of 2018 fees under a 10-year contractor agreement, and controlled the board that approves credit-facility draws. The filing also reports 2018 expenses of $45,000 under a consulting agreement with Emerald’s chairman, later cancelled.
Important facts for investors to verify
- Reconcile the registrant identity: this document is Nemus Bioscience, Inc., while the request metadata identifies Skye Bioscience, Inc.; confirm the intended issuer and any later corporate name or successor changes.
- Confirm current cash, cash burn, obligations, and financing availability, including remaining facility capacity and board approval conditions; the going-concern warning is substantial.
- Review the terms, classification, valuation assumptions, and potential dilution from Emerald’s warrants, conversion rights, and derivative liabilities. The filing’s stated ownership percentages differ depending on whether warrants are included.
- Check the status and outcome of the $20 million arbitration claim and whether the company continued pursuing it.
- Verify subsequent regulatory and development progress for NB1111 and the other candidates; reported efficacy evidence is preclinical, and no product was approved or generating revenue at year-end.